• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    11/14/24 4:08:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPSC alert in real time by email
    SC 13G/A 1 d11528763_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Century Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

    15673T100
    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [ ] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 15673T100    

     

    1. NAME OF REPORTING PERSONS  
         
      Casdin Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,212,316  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,212,316  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,212,316  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      3.8%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA 

     
         
     
     

     

    CUSIP No 15673T100    

     

    1. NAME OF REPORTING PERSONS  
         
      Eli Casdin  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,212,316  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,212,316  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,212,316  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      3.8%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     
     
     

     

    CUSIP No 15673T100    

     

    Item 1. (a). Name of Issuer:  
           
        Century Therapeutics, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    25 North 38th Street, 11th Floor

    Philadelphia, Pennsylvania 19104

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Casdin Capital, LLC

    Eli Casdin

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Casdin Capital, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Eli Casdin

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

     

      (c). Citizenship:  
           
       

    Casdin Capital, LLC - Delaware

    Eli Casdin– United States of America

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, $0.0001 par value per share  

     

      (e). CUSIP Number:  
           
        15673T100  
           
    Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    3,212,316 shares deemed beneficially owned by Casdin Capital, LLC

    3,212,316 shares deemed beneficially owned by Eli Casdin

     

      (b)   Percent of class:
         
       

    3.8% deemed beneficially owned by Casdin Capital, LLC

    3.8% deemed beneficially owned by Eli Casdin

     

      (c)   Number of shares as to which Casdin Capital, LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 3,212,316 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 3,212,316 .

     

      Number of shares as to which Eli Casdin has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 3,212,316 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 3,212,316 .

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

         
     

     

     
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        November 14, 2024  
        (Date)  

     

     

    Casdin Capital, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
      Eli Casdin

     

     

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G amendment dated November 14, 2024 relating to the Common Stock, $0.0001 par value per share of Century Therapeutics, Inc., shall be filed on behalf of the undersigned.

     

    Casdin Capital, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

       
      /s/ Eli Casdin
      Eli Casdin

     

     

     

     

     

     

    Get the next $IPSC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IPSC

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00Buy
    Rodman & Renshaw
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    12/27/2022$19.00Buy
    Chardan Capital Markets
    10/31/2022$15.00Buy
    Guggenheim
    10/10/2022$28.00Buy
    Canaccord Genuity
    5/23/2022$27.00Buy
    H.C. Wainwright
    5/12/2022Mkt Perform
    William Blair
    11/19/2021$33.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $IPSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer Farid Adrienne sold $563 worth of shares (1,024 units at $0.55), decreasing direct ownership by 0.41% to 250,693 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:50 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP Finance & Operations Carr Douglas sold $162 worth of shares (295 units at $0.55), decreasing direct ownership by 0.07% to 410,886 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      5/7/25 4:38:25 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Finanical Officer Conn Morgan was granted 19,500 shares, increasing direct ownership by 32% to 79,648 units (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      3/12/25 7:31:34 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Financials

    Live finance-specific insights

    See more
    • Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

      - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest

      5/9/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

      – Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – –   Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1

      12/9/23 12:00:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

      PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re

      12/6/23 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Century Therapeutics Inc.

      DEFA14A - Century Therapeutics, Inc. (0001850119) (Filer)

      4/22/25 4:07:45 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Century Therapeutics Inc.

      DEF 14A - Century Therapeutics, Inc. (0001850119) (Filer)

      4/22/25 4:06:02 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Century Therapeutics Inc.

      S-8 - Century Therapeutics, Inc. (0001850119) (Filer)

      3/20/25 7:30:44 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $IPSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IPSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IPSC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form SC 13G filed by Century Therapeutics Inc.

      SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

      11/27/24 6:51:58 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 5:46:35 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

      SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

      11/14/24 4:08:17 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Quimi Daphne bought $7,657 worth of shares (5,000 units at $1.53) (SEC Form 4)

      4 - Century Therapeutics, Inc. (0001850119) (Issuer)

      9/16/24 4:18:18 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

      8/8/24 10:22:51 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics downgraded by JP Morgan with a new price target

      JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously

      8/28/23 7:15:43 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets initiated coverage on Century Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00

      12/27/22 7:45:12 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

      PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows:

      4/28/25 4:30:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

      PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer. The event will feature discussion of CNTY-308, a CD19-targeted CAR-iT investigational cell therapy, CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy, and the company's first solid tumor CAR

      4/15/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highligh

      3/19/25 4:01:00 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IPSC
    Leadership Updates

    Live Leadership Updates

    See more
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

      - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en

      3/14/24 7:30:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

      - Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a who

      11/9/23 7:00:00 AM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care